Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
The anti-epileptic medicine Keppra (levetiracetam) may have a neuroprotective effect for spinal muscular atrophy (SMA), according to a recent study. The study, “The Protective Effects of Levetiracetam on a Human iPSCs‑Derived Spinal ... Read more
A noninvasive method of detecting the presence of the SMN protein in blood samples may become the gold standard for evaluating and monitoring new therapeutic strategies for spinal muscular ... Read more
Degree of motor skills, and the intensity of feelings of depression and fatigue influence the degree to which adults with spinal muscular atrophy (SMA), regardless of subtype, participate in and ... Read more
Japanese researchers have identified ways to measure the swallowing difficulties of people with spinal and bulbar muscular atrophy, or SBMA.
Two ways in particular could be useful in clinical trials, they ... Read more
Researchers have provided new insight into the activation process of myostatin, which is targeted by the antibody SRK-015 — a potential treatment for spinal muscular atrophy (SMA). The study, ... Read more
The U.K’s National Institute for Health and Care Excellence (NICE) has formally invited Biogen to submit Spinraza (nusinersen) for Single Technology Appraisal (STA) on its course toward possible NHS funding. ... Read more
Parents of children with spinal muscular atrophy (SMA) advise healthcare professionals to be more mindful of professional-family relations, improve and be willing to share their knowledge about SMA, and ... Read more
Cure SMA will host a webinar on spinal muscular atrophy (SMA) today at 1 p.m. EST. The event focuses on access to Spinraza — the only U.S. government-approved therapy to treat ... Read more
Pin It on Pinterest